Celmatix Inc. is a preclinical-stage biotech company founded with the mission to transform women's lives through better ovarian health. The company focuses on ovarian biology and aims to address high unmet needs in women's health. Its lead program, AMHR2, targets ovarian senescence, and it has collaborations in polycystic ovary syndrome (PCOS) and non-hormonal contraception with industry leaders. Celmatix's market focus is on innovative treatments for conditions caused by poor ovarian health, which affect one in three women.
Notable affiliated people include industry leaders in women's health and biotech. Key investors have supported Celmatix in advancing its research and development efforts. The company's achievements include pioneering a "pipeline-in-a-pill" approach and establishing significant collaborations to tackle PCOS and non-hormonal contraception. Overall, Celmatix has made a substantial impact by addressing critical gaps in women's health, particularly in ovarian biology, and is poised to change the future of medicine in this field.
